Correspondence 0001731122-24-001735 from Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Virpax Pharmaceuticals, Inc. (VRPX) (CIK 0001708331)
Date: Nov. 6, 2024 · CIK: 0001708331 · Accession: 0001731122-24-001735
AI Filing Summary & Sentiment
File numbers found in text: 333-281080
Letter
Re: Virpax Pharmaceuticals, Inc.
November 6, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Doris Stacey Gama
Registration Statement on Form S-1, as amended
File No. 333-281080
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: Friday, November 8,
Requested Time: 9:00 a.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), we, the undersigned, as the sole placement agent for the proposed public offering on a best efforts basis of securities of Virpax Pharmaceuticals, Inc. (the “Company”), hereby join the Company’s request that the effective date of the above-referenced registration statement on Form S-1, as amended, be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on Friday, November 8, 2024, or as soon thereafter as possible.
Pursuant to Rule 460 under the Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
SPARTAN CAPITAL SECURITIES,
LLC
Show Raw Text
CORRESP
1
filename1.htm
November 6, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Doris Stacey Gama
Re: Virpax Pharmaceuticals, Inc.
Registration
Statement on Form S-1, as amended
File No. 333-281080
REQUEST FOR ACCELERATION OF EFFECTIVENESS
Requested Date: Friday, November 8,
2024
Requested Time: 9:00 a.m., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the
Securities Act of 1933, as amended (the “Securities Act”), we, the undersigned, as the sole placement agent for the proposed
public offering on a best efforts basis of securities of Virpax Pharmaceuticals, Inc. (the “Company”), hereby join the Company’s
request that the effective date of the above-referenced registration statement on Form S-1, as amended, be accelerated so that it will
be declared effective at 9:00 a.m., Eastern Time, on Friday, November 8, 2024, or as soon thereafter as possible.
Pursuant to Rule 460 under the
Securities Act, please be advised that we will distribute as many copies of the proposed form of preliminary prospectus as appears to
be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned advises that it
has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
SPARTAN CAPITAL SECURITIES,
LLC
By:
/s/ Kim Monchik
Name:
Kim Monchik
Title:
Chief Administrative Officer